WO2005020876A3 - Pharmaceutical composition, method of manufacturing and therapeutic use thereof - Google Patents

Pharmaceutical composition, method of manufacturing and therapeutic use thereof Download PDF

Info

Publication number
WO2005020876A3
WO2005020876A3 PCT/CZ2004/000053 CZ2004000053W WO2005020876A3 WO 2005020876 A3 WO2005020876 A3 WO 2005020876A3 CZ 2004000053 W CZ2004000053 W CZ 2004000053W WO 2005020876 A3 WO2005020876 A3 WO 2005020876A3
Authority
WO
WIPO (PCT)
Prior art keywords
manufacturing
pharmaceutical composition
oxaliplatin
animal origin
therapeutic use
Prior art date
Application number
PCT/CZ2004/000053
Other languages
French (fr)
Other versions
WO2005020876A2 (en
Inventor
Borek Zaludek
Jan Boleslav
Vladimir Kysilka
Jiri Verner
Hana Brzobohata
Bozena Matejkova
Milan Kakrda
Original Assignee
Pliva Lachema As
Borek Zaludek
Jan Boleslav
Vladimir Kysilka
Jiri Verner
Hana Brzobohata
Bozena Matejkova
Milan Kakrda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Lachema As, Borek Zaludek, Jan Boleslav, Vladimir Kysilka, Jiri Verner, Hana Brzobohata, Bozena Matejkova, Milan Kakrda filed Critical Pliva Lachema As
Priority to US10/569,866 priority Critical patent/US20060275331A1/en
Priority to JP2006525029A priority patent/JP2007504177A/en
Priority to CA002537610A priority patent/CA2537610A1/en
Priority to EP04762305A priority patent/EP1663106A2/en
Publication of WO2005020876A2 publication Critical patent/WO2005020876A2/en
Publication of WO2005020876A3 publication Critical patent/WO2005020876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, wherein the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7. The invention also relates to the method of manufacturing of said composition and to the use of this composition in the treatment of tumors sensitive to oxaliplatin.
PCT/CZ2004/000053 2003-09-02 2004-08-31 Pharmaceutical composition, method of manufacturing and therapeutic use thereof WO2005020876A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/569,866 US20060275331A1 (en) 2004-08-31 2004-08-31 Pharmaceutical composition, method of manufacturing and therapeutic use thereof
JP2006525029A JP2007504177A (en) 2003-09-02 2004-08-31 Pharmaceutical composition, process for its production and therapeutic use
CA002537610A CA2537610A1 (en) 2003-09-02 2004-08-31 Pharmaceutical composition, method of manufacturing and therapeutic use thereof
EP04762305A EP1663106A2 (en) 2003-09-02 2004-08-31 Pharmaceutical composition, method of manufacturing and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZPV2003-2367 2003-09-02
CZ20032367A CZ300795B6 (en) 2003-09-02 2003-09-02 Pharmaceutical composition and process for its preparation

Publications (2)

Publication Number Publication Date
WO2005020876A2 WO2005020876A2 (en) 2005-03-10
WO2005020876A3 true WO2005020876A3 (en) 2005-06-09

Family

ID=34256928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2004/000053 WO2005020876A2 (en) 2003-09-02 2004-08-31 Pharmaceutical composition, method of manufacturing and therapeutic use thereof

Country Status (6)

Country Link
EP (1) EP1663106A2 (en)
CA (1) CA2537610A1 (en)
CZ (1) CZ300795B6 (en)
PL (1) PL366975A1 (en)
RU (1) RU2329052C2 (en)
WO (1) WO2005020876A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090102844A (en) * 2007-01-22 2009-09-30 플리바-라케마 에이. 에스. Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer
CZ300664B6 (en) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterile liquid pharmaceutical composition and process for preparing thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012193A1 (en) * 1992-11-24 1994-06-09 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
DE10314377A1 (en) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
PT1207875E (en) * 1999-08-30 2004-02-27 Debiopharm Sa PHARMACEUTICAL PREPARATION OF OXALIPLATIN STABILIZER FOR ADMINISTRATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012193A1 (en) * 1992-11-24 1994-06-09 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
DE10314377A1 (en) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATHÉ G ET AL: "Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, PARIS, FR, vol. 43, 1989, pages 237 - 250, XP002094674, ISSN: 0753-3322 *

Also Published As

Publication number Publication date
CA2537610A1 (en) 2005-03-10
RU2006110563A (en) 2006-08-10
RU2329052C2 (en) 2008-07-20
CZ300795B6 (en) 2009-08-12
PL366975A1 (en) 2005-03-07
WO2005020876A2 (en) 2005-03-10
CZ20032367A3 (en) 2005-04-13
EP1663106A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2004005286A3 (en) Viral inhibitors
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2005018574A3 (en) Immunostimulatory combinations and treatments
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2006093784A3 (en) Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
WO2005000232A3 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2001000566A3 (en) Substituted phenoxyacetic acids
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
WO2005077951A3 (en) 7h-pyrrolopyrimidine derivatives
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2005020876A3 (en) Pharmaceutical composition, method of manufacturing and therapeutic use thereof
NO331205B1 (en) Pharmaceutical composition as solid dosage form and method of preparation thereof
CA2505500A1 (en) Method of stimulating hair growth using benzopyrans
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
WO2005030785A3 (en) Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006275331

Country of ref document: US

Ref document number: 10569866

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2537610

Country of ref document: CA

Ref document number: 2006525029

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004762305

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006110563

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004762305

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10569866

Country of ref document: US